Differential effect of resveratrol on nitric oxide production in endothelial F-2 cells

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 11, 2009, Pages 1840-1843

  Takahashi, Satoru ^a   Uchiyama, Tomomi ^a   Toda, Ken Ichi ^b  

^a KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b Kitano Hospital   (Japan)

Author keywords

Endothelial cell; Nitric oxide; Resveratrol

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CALCIUM ION; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; RESVERATROL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CALCIUM DEPLETION; CELL ASSAY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; EXTRACELLULAR CALCIUM; MOLECULAR MECHANICS; MOUSE; NONHUMAN;

ANIMALS; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STILBENES;

EID: 70350712282     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.1840     Document Type: Article

References (24)

1. Frémont L., Life Sci., 66, 663-673 (2000).
2. Stoclet J.-C., Chataigneau T., Ndiaye M., Oak M.-H., Bedoui J. E., Chataigneau M., Schini-Kerth V. B., Eur. J. Pharmacol., 500, 299-313 (2004).
3. Wallerath T., Deckert G., Ternes T., Anderson H., Li H., Witte K., Förstermann U., Circulation, 106, 1652-1658 (2002).
4. Räthel T. R., Samtleben R., Vollmar A. M., Dirsch V. M., J. Hypertens., 25, 541-549 (2007).
5. Nicholson S. K., Tucker G. A., Brameld J. M., Proc. Nutr. Soc., 67, 42-47 (2008).
6. Chen C. K., Pace-Asciak C. R., Gen. Pharmacol. Soc., 27, 363-366 (1996).
7. Orallo F., Alvarez E., Camiña M., Leiro J. M., Gómez E., Fernández P., Mol. Pharmacol., 61, 294-302 (2002).
8. Li H., Tian Z. F., Qiu X. Q., Wu J. X., Zhang P., Jia Z. J., Physiol. Res., 55, 365-372 (2006).
9. Fitzpatrick D. F., Hirschfield S. L., Coffey R. G., Am. J. Physiol., 265, H774-H778 (1993).
10. Taubert D., Berkels R., Klaus W., Roesen R., J. Cardiovasc. Pharmacol., 40, 701-713 (2002).
11. Ignarro L. J., Cirino G., Casini A., Napoli C., J. Cardiovasc. Pharmacol., 34, 879-886 (1999).
12. Takahashi S., Mendelsohn M. E., J. Biol. Chem., 278, 9339-9344 (2003).
13. Takahashi S., Mendelsohn M. E., J. Biol. Chem., 278, 30821-30827 (2003).
14. Dudzinski D. M., Michel T., Cardiovasc. Res., 75, 247-260 (2007).
15. Toda K., Tsujioka K., Maruguchi Y., Ishii K., Miyachi Y., Kuribayashi K., Imamura S., Cancer Res., 50, 5526-5530 (1990).
16. Wang Y., Shin W. S., Kawaguchi H., Inukai M., Kato M., Sakamoto A., Uehara Y., Miyamoto M., Shimamoto N., Korenaga R., Ando J., Toyo-oka T., J. Biol. Chem., 271, 5647-5655 (1996).
17. Takahashi S., Nakamura E., Okabe S., Dig. Dis. Sci., 43, 2301-2308 (1998).
18. Fulton D., Gratton J.-P., McCabe T. J., Fontana J., Fujio Y., Walsh K., Franke T. F., Papapetropoulos A., Sessa W. C., Nature (London), 399, 597-601 (1999).
19. Stoclet J. C., Kleschyov A., Andriambeloson E., Diebolt M., Andriantsitohaina R., J. Physiol. Pharmacol., 50, 535-540 (1999).
20. Scifo C., Cardile V., Russo A., Consoli R., Vancheri C., Capasso F., Vanella A., Renis M., Oncol. Res., 14, 415-426 (2004).
21. Klinge C. M., Blankenship K. A., Risinger K. F., Bhatnagar S., Noisin E. L., Samanasekera W. K., Brey D. M., Keynton R. S., J. Biol. Chem., 280, 2701-2712 (2003).
22. Ashby J., Tinwell H., Pennie W., Brooks A. N., Lefevre P. A., Beresford N., Sumpter J. P., J. Appl. Toxicol., 19, 39-45 (1999).
23. Ndiaye M., Chataigneau T., Andriantsitohaina R., Stoclet J. C., Schini-Kerth V. B., Biochem. Biophys. Res. Commun., 310, 371-377 (2003).
24. Leblais V., Krisa S., Valls J., Courtois A., Abdelouhab S., Vila A. M., Mérillon J. M., Muller B., Fundam. Clin. Pharmacol., 22, 25-35 (2008).